Top Markets
Coin of the day
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
株式のランク #30249
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
株価
$1.88
最終同期: 2026-08-18
時価総額
$17.59M
変化(1日)
0.81%
変化(1年)
-92.40%
US
取引 Tvardi Therapeutics, Inc. (TVRD)

カテゴリー

Tvardi Therapeutics, Inc.(TVRD)のEPS
2026 時点のEPS TTM: 0
Tvardi Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Tvardi Therapeutics, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS